KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Accured Expenses (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Change in Accured Expenses for 17 consecutive years, with $44.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 183.07% year-over-year to $44.2 million, compared with a TTM value of $66.1 million through Dec 2025, up 348.05%, and an annual FY2025 reading of $66.1 million, up 348.05% over the prior year.
  • Change in Accured Expenses was $44.2 million for Q4 2025 at Biomarin Pharmaceutical, up from $18.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $81.4 million in Q3 2023 and bottomed at -$78.1 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $7.7 million, with a median of $2.2 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 3491.62% in 2022, then skyrocketed 4958.35% in 2023.
  • Year by year, Change in Accured Expenses stood at -$3.6 million in 2021, then surged by 382.52% to $10.2 million in 2022, then rose by 22.93% to $12.5 million in 2023, then tumbled by 525.38% to -$53.3 million in 2024, then skyrocketed by 183.07% to $44.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for BMRN at $44.2 million in Q4 2025, $18.8 million in Q3 2025, and $1.0 million in Q2 2025.